US Patent Issued to SYNGLE THERAPEUTICS on Nov. 4 for "Alpha-synuclein binding antibodies, or antigen binding portions thereof" (Dutch, Belgian Inventors)

ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,459,998, issued on Nov. 4, was assigned to SYNGLE THERAPEUTICS B.V. (Soest, Netherlands).

"Alpha-synuclein binding antibodies, or antigen binding portions thereof" was invented by Augustinus Petrus Henricus Scheefhals (Soest, Netherlands), Wilbrandt Jannes Wichert Tepper (Soest, Netherlands) and Erik Stoops (Zwalm, Belgium).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to an isolated antibody, or antigen-binding portion thereof, with a higher binding affinity to alpha-synuclein oligomers compared to alpha-synuclein fibrils and/or alpha-synuclein monomers. The invention further describes in vitro and/or ex vivo methods using ...